Human Chorionic Gonadotropin and CA 15-3 Producing Adenocarcinoma

G. Üçkaya; A. Özet; A. Arpaci; S. Kömiircü

doi:10.1055/s-0038-1632352

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 1998; 37(08): 297-298
DOI: 10.1055/s-0038-1632352

Originalarbeiten — Original Articles

Schattauer GmbH

Human Chorionic Gonadotropin and CA 15-3 Producing Adenocarcinoma

Human Chorionic Gonadotropin und das CA 15-3 produzierende Adenokarzinom der Lunge

Authors

G. Üçkaya

¹Department of Internal Disease, Gülhane Military Medical Academia, Ankara, Turkey
A. Özet

²Department of Medical Oncology, Gülhane Military Medical Academia, Ankara, Turkey
A. Arpaci

²Department of Medical Oncology, Gülhane Military Medical Academia, Ankara, Turkey
S. Kömiircü

²Department of Medical Oncology, Gülhane Military Medical Academia, Ankara, Turkey

Abstract

Summary

50 years old man suffering from primary lung adenocarcinoma presented with high levels of both beta subunit human chorionic gonadotropin (βHCG) and cancer antigen 15-3 (CA 15-3) in the absence of elevated carcinoembrionic antigen (CEA), alfa fetoprotein (AFP) and carbohydrate antigen 19-9 (CA 19-9). Although βHCG or CA 15-3 high levels were reported in adenocarcinoma of lung, this is the first report of a patient with high levels of both markers.

Zusammenfassung

Im Blut eines 50jährigen Mannes, der an einem primären Adenokarzinom der Lunge litt, wurden hohe Werte für die Spiegel der beiden Sub- unit-Formen von Human Chorionic Gonadotropin (βHCG) und Krebsantigen 15-3 gefunden, während die Spiegel von CEA, AFP und CA 19-9 normal waren. Obwohl hohe Anteile an βHCG und an Ca 15-3 vorher bekannt waren handelt es sich um den ersten Bericht mit hohen Blutspiegeln für beide Krebsmarker.

Keywords

Lung cancer - tumor markers - βHCG - CA 15-3

Schlüsselwörter

Lungenkarzinom - Tumormarker - βHCG - CA 15-3

Full Text

References

References
1 DeVita Jr. VT, Hellman S, Rosenberg SA. Cancer principles and practice of oncology.. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997: 546-52.
2 Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology.. London: Blackwell Scientific Publications; 1992: 301-60.
3 Klepp O, Romslo I. Tumor markers – an update: Proceeding from the first meeting on tumor markers. Trondheim. 1991: 8-105.
4 Daar AS, Lennox ES. Tumor markers.. London: Blackwell Scientific Publications; 1987: 1-23.
5 Fateh-Moghadam A, Stieber P. Sensible use of tumor markers.. Basel, Switzerland: Roch; 1993
6 Kimura N, Ghandur-Mnaymen L. An Immunohistochemical study of keratin, carcinoembriyonic antigen, human chorionic gonadotropin and alpha-feto protein in lung cancer. Tohoku J. Exp Med 1985; 145: 23-38.
7 Nöda Y, Simodaira M, Ito H. Two cases of HCG producing large cell carcinoma accompanied with gynecomastia. Nippon Kyobu Gakkai. Zasshi 1990; 28: 781-5.
8 Fukuda M, Sasaki Y, Morita M. Large cell carcinoma of the lung secreting HCG which responded to combination chemotherapy: case report. Jpn J Cli. Oncol 1990; 20: 299-305.
9 Yoshimura M, Nishimura R, Murotani A. Assesment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer. Cancer 1994; 73: 2745-52.
10 Huang SC, Hsieh CY, Hwang JL, Ouyang PC, Chen HC. Free alpha subunit of HCG in women with non-trophoblastic tumors. Taiwan I. Hsueh. Hui Tsa Chih 1989; 88: 218-25.
11 Colomer R, Ruibal A, Genolla J, Salvador L. Circulating CA 15-3 levels in non-mammary malignencies. Br. J. Cancer 1989; 59: 283-6.